Review of Monoclonal Antibodies for the Treatment of Crohn’s Disease

CE-3 2023 Deadline for submission: 31 OCT 2023

Overview of the drug therapy for Psoriasis

CE-2 2023 Deadline for submission: 31 Jul 2023

COVID-19: Update on Evidence for a Pre-Exposure Prophylaxis Strategy versus Post-Exposure Prophylaxis

CE-1 2023 Deadline for submission: 28 Feb 2023

Management of Hospital-acquired Pneumonia and Ventilator-associated Pneumonia: The Conventional and Novel Antimicrobials

CE-2 2022 Deadline for submission: 31 Oct 2022

Recent Development of Lipid Management: PCSK9 Inhibitors and Inclisiran

CE-1 2022 Deadline for Submission: 31 Aug 2022

Tumour Lysis Syndrome

CE-3 2021 Deadline for Submission: 30 Nov 2021


Cardiovascular and Renal Benefits of SGLT-2 Inhibitors – Is It a Class Effect

CE-2 2021 Deadline for Submission: 31 Jul 2021

Pharmacokinetic drug interaction of protein kinase inhibitors

CE-1 2021 Deadline for Submission: 28 Feb 2021

Pharmacist-led Smoking Cessation: Pharmacological and Non-Pharmacological Options

CE-5 2020


COVID-19: An Overview of its Transmission, Management and Prevention Strategies

CE-4 2020

Medication Management in Patients Undergoing Surgery

CE-3 2020

Review of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Nausea and Vomiting

CE-2 2020

Spinal Muscular Atrophy: A Treatment Update

CE-1 2020

Dronedarone: A Review in Atrial Fibrillation

CE-3 2019

Update on Drug Treatments for Idiopathic Pulmonary Fibrosis for Hong Kong Pharmacists


CE-2 2019 Deadline for Submission 31 Mar 2019


Management Approach of Hemophilia A and B


CE-1 2019 Deadline for Submission 31 Mar 2019


Edoxaban - A New Direct Oral Anticoagulant

CE-8 2018 Deadline for Submission 30 Nov 2018

Eteplirsen: A Novel Gene Therapy for Duchenne Muscular Dystrophy


CE-7 2018 Deadline for Submission 30 Nov 2018


Promising new developments in our fight against Drug-resistant Mycobacterium tuberculosis (TB)


CE-6 2018 Deadline for Submission 31 Oct 2018


Review of Newly Registered Anticoagulants and a Reversal Agent for Dabigatran: Bivalirudin, Edoxaban and Idarucizumab


CE-5 2018 Deadline for Submission 30 Sep 2018